Clinical Studies: 2006 Start Date

Arthritis with Cardiovascular Disease
Sponsor: Pfizer
A Randomized, Double Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patient With or at High Risk for Cardiovascular Disease Comparing XXXXX with Naproxen and Ibuprofen.
December 2006 to Present

Atopic Dermatitis
Sponsor: Ceragenix
A Prospective, Randomized, Investigator-Blind, Controlled, Pilot Study Comparing The Effect of the EpiCeram Device versus Conservative Standard of Care Therapy Utilizing Mid-Strength Topical Steroid XXXXX in the Treatment of Atopic Dermatitis in Pediatric Subjects
November 2006 to May 2007

Acne
Sponsor: Galderma R&D Inc.
A Multi-Center, Randomized, Double-blind, Parallel Group Study to Demonstrate Safety and Efficacy of a Fixed-Combination of a Topical Retinoid and Benzoyl Peroxide 2.5% Gel Compared With the Monads and Corresponding Topical Gel Vehicle.
October 2006 to June 2007

Acne
Sponsor: Johnson & Johnson
An Open-label, Community Based, Phase Four Study to Assess Facial Acne Improvement with Use of XXXXX in a Pump Dispenser.
September 2006 to June 2007

Psoriasis
Sponsor: Amgen, Inc.
Observational Post-Marketing Safety Surveillance Registry of XXXXX for the Treatment of Psoriasis.
July 2006 to Present

Psoriasis
Sponsor: Genentech, Inc.
A Phase IV, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXXXX in Adult Subject with Moderate to Severe Psoriasis Who Have Had an Inadequate Response to an Anti-TNF Agent.
July 2006 to Present

Acne
Sponsor: Allergan
A Clinical Evaluation of XXXXX Indicated for the Topical Treatment of Patients with Acne Vulgaris, Who Do Not Want To or Are Unable to Participate in the iPLEDGE Program.
May 2006 to July 2006

Psoriasis
Sponsor: Galderma Laboratories, L.P.
A Phase IV, Open-Label, Multicenter, Community-based, 4-Week Trial Assessing Efficacy, Tolerance to Treatment, and Patient Satisfaction With XXXXX When Used as Monotherapy or as Add-on Therapy to Existing Systemic or Topical Anti-psoriatic Agents for the Treatment of Moderate to Sever Plaque Psoriasis.
February 2006 to June 2006

Acne
Sponsor: Concordia Clinical Research, Inc.
A Phase IV, Open-Label, Multicenter, Community-based, 4-Week Trial Assessing Efficacy, Tolerance to Treatment, and Subject Satisfaction with XXXXX.
March 2006 to June 2006

Type 2 Diabetes
Sponsor: Eli Lilly and Company
The DURABLE Trial: Assessing the Durability of Basal vs. Lispro Mix 25 Insulin Efficacy.
March 2006 to October 2008

Psoriasis
Sponsor: Centocor, Inc.
A Phase 3 Trial Evaluating the Efficacy and Safety of XXXXX in the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis. (T09)
January 2006 to Present

Psoriasis
Sponsor: Genentech, Inc.
A Phase IV, Randomized, Double-Blind, Placebo Controlled Study To Evaluate The Safety and Efficacy of 1.0 mg/kg XXXXX in Adult Patients With Moderate to Severe Plaque Psoriasis Involving the Hands and/or Feet.
January 2006 to April 2007

Psoriasis
Sponsor: Centocor, Inc.
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of XXXXX in the treatment of Subjects With Moderate to Severe Plaque-type Psoriasis. (T08)
January 2006 to Present

Psoriatic Arthritis
Sponsor: Centocor, Inc.
A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of XXXXX a Fully Human Anti-IL-12 Monoclonal Antibody, Administered Sub-Cutaneously, in Subjects with Active soriatic Arthritis. (T10)
January 2006 to November 2007

Clinical Studies